Inventor · disambiguated record
Alfredo Grossi
Also filed as: GROSSI ALFREDO
17 granted patents·21 pending applications·69 citations·filing 1984–2024
93Inventor score
Files withSCPHARMACEUTICALS INC10IRONWOOD PHARMACEUTICALS INC8VERTEX PHARMA6FRETZEN ANGELIKA4FOREST LAB HOLDINGS LTD3
Top patents by PatentIndex Score
38 records- 0197US10646481B2Pharmaceutical composition and administrations thereofVERTEX PHARMA·Filed 2016·Granted May 12, 2020·21 cites·26 claims
- 0296US11564916B2Pharmaceutical composition and administrations thereofVERTEX PHARMA·Filed 2020·Granted Jan 31, 2023·7 cites·40 claims
- 0394US12491197B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2024·Granted Dec 9, 2025·1 cites·24 claims
- 0494US12491193B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2024·Granted Dec 9, 2025·1 cites·20 claims
- 0594US12491195B2Concentrated liquid pharmaceutical Formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2024·Granted Dec 9, 2025·1 cites·22 claims
- 0694US12491194B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2024·Granted Dec 9, 2025·1 cites·28 claims
- 0794US12491196B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2024·Granted Dec 9, 2025·1 cites·25 claims
- 0890US8748573B2Formulations comprising linaclotideFRETZEN ANGELIKA·Filed 2010·Granted Jun 10, 2014·8 cites·10 claims
- 0986US8802628B2Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administrationFRETZEN ANGELIKA·Filed 2009·Granted Aug 12, 2014·7 cites·26 claims
- 1083US12048709B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2023·Granted Jul 30, 2024·0 cites·34 claims
- 1183US11559535B2Concentrated liquid pharmaceutical formulations of furosemideSCPHARMACEUTICALS INC·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
- 1283US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1382US11998555B2Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the sameSCPHARMACEUTICALS INC·Filed 2020·Granted Jun 4, 2024·1 cites·20 claims
- 1481US11571434B2Concentrated liquid pharmaceutical formulations of furosemideSCPHARMACEUTICALS INC·Filed 2022·Granted Feb 7, 2023·0 cites·20 claims
- 1581US11497755B2Concentrated liquid pharmaceutical formulations of furosemideSCPHARMACEUTICALS INC·Filed 2022·Granted Nov 15, 2022·0 cites·22 claims
- 1678US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1775US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1870US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1966US2010074949A1Pharmaceutical composition and administration thereofROWE WILLIAM·Filed 2009·Application pending·0 cites
- 2065US12458635B2Pharmaceutical composition and administrations thereofVERTEX PHARMA·Filed 2022·Granted Nov 4, 2025·0 cites·17 claims
- 2165US2019029967A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2262US2012009225A1Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral AdministrationFRETZEN ANGELIKA·Filed 2009·Application pending·0 cites
- 2361US2013273169A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 2460US2013190239A1Formulations Comprising LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2560US2015132375A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2659US2014112988A1Pharmaceutical Composition and Administrations ThereofVERTEX PHARMA·Filed 2013·Application pending·0 cites
- 2757US2014315948A1Pharmaceutical Composition and Administrations ThereofVERTEX PHARMA·Filed 2014·Application pending·0 cites
- 2854US2015031632A1Orally Disintegrating Compositions of LinaclotideFOREST LAB HOLDINGS LTD·Filed 2014·Application pending·0 cites
- 2952US2012258983A1Pharmaceutical Composition and Administrations ThereofROWE WILLIAM·Filed 2012·Application pending·0 cites
- 3051US2014349948A1Treatment of Chronic ConstipationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 3151US2012039949A1Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral AdministrationFRETZEN ANGELIKA·Filed 2009·Application pending·0 cites
- 3247US2021338782A1Storage stable somatostatin-dopamine chimeric compounds and salt forms thereofCYDAN II INC·Filed 2021·Application pending·0 cites
- 3347US2010256184A1Pharmaceutical composition and administrations thereofVERTEX PHARMA·Filed 2010·Application pending·0 cites
- 3443US2013059797A1Linaclotide for the Treatment of Chronic ConstipationJOHNSTON JEFFREY·Filed 2010·Application pending·0 cites
- 3539US5224302ADevice for re-conditioning cutting elements of disposable double-blade shaversGROSSI ALFREDO·Filed 1992·Granted Jul 6, 1993·10 cites·13 claims
- 3639US2012220625A1Pharmaceutical composition and administrations thereofROWE WILLIAM·Filed 2012·Application pending·0 cites
- 3738US4586587AElevator brake control method and arrangementGROSSI ALFREDO·Filed 1984·Granted May 6, 1986·10 cites·9 claims
- 3836US2013012454A1Orally Disintegrating Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →